The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I agree oil, didn't hear that. It's interesting...he said about the national trials using 'existing' drugs. That turn of phrase has been used by ministers and doctors to describe the recovery trial, not SNG as they truly are existing drugs, so why include the sixth drug (sng) in with that? I'm with you miggy, only time will tell!
I'm not sure about the scale on the graph but if 1 equals every patient then by my crude working out just over half the patients entering hospital have COPD or asthma. If somebody else could look at the chart and make sure my working out is roughly accurate.
So I've just tried to add up the proportion of patients with either COPD and/or Asthma from the ISARIC report that enter hospital with covid 19 compared to other co-morbidities and it is the highest co-morbidity. In fact there's twice as many with either COPD/Asthma than cardiac disease, and 3 times more than diabetes. Very interesting.
Sharesting Chronic Pulmonary Disease is COPD so you've got Asthma and COPD as 2 of the top 4 co-morbidities of patients entering hospital, the top two being cardiac disease and diabetes. No doubt there's some overlap too. I suppose it's no surprise but good to see it in writing. Let's hope it works...
I don't think the CE Mark validates the specificity and sensitivity of the test.
True, stumbled a bit to say the right thing....hmm
He said they don't have one yet that is 'clinically valid'...surely they've completed the validation exercise at phe?
I like this sentence,
'the ability of type I IFNs to induce an anti-viral programme in parallel with this effect should actually prepare the cells to respond better to the infection and enhance their ability to fight off the virus'
C'mon SNG!!!
Sharesting I didn't say they were limited to hospital treatment, I said they appear to be limited to symptoms. I'm merely pointing out that if the treatment works best when the patient has been infected for a shorter period of time they might not all have the symptoms to qualify for the patent. I'm not an IP specialist but think it's worth raising as we know the direction this is going...
https://patents.google.com/patent/WO2011110861A2/nl
As somebody brought up patents earlier I thought I would post the patent. Don't think it's an issue, and I'm sure this has been discussed before, seems very broad covering influenza like illness with temperature over 37.8 and 2 of cough/sore throat/myalgia/headache...I would imagine that would cover 99% of hospitalised patients. Not sure about use in home though if symptoms at early stage, you may not tick all the boxes.
I don't buy into the, 'if you don't believe in the product, you shouldn't be investing or be on here', like Jack says it's a dynamic situation, if a paper came out tomorrow that categorically said inhaled ifn beta 1a causes more harm than good with Sars- COV 2 I'd like to think our armchair research would help you lose less money. I have full confidence the synairgen team know everything about their product, however I don't have full confidence they know everything about sars COV 2...
Anyway keep researching everyone...
I don't think we are ever going to fully understand the relationship between ifn,sars COV 2 and ACE2 receptors on this group as we are not experts, if there are any please make yourself known! I broadly think manifesto is right, these guys know how their drug works and the best time to administer it. However it is a novel virus so nobody knows how it will respond in the trial. It does help me personally to back my investment with these conversations and researching papers, and I'm still here so I must be reasonably confident...
The article I read showed sars COV 2 binding less to ACE 2 receptor than sars COV 1 so that should mean the virus having a lower impact. Sars COV was more deadly in terms of deaths per infection I think?? Could be wrong. Anyway we are probably oversimplifying it